.. Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD Aeterna Zentaris Inc.S. Food and Drug Administration has accepted for filing the Firm's New Medication Application for its ghrelin agonist, macimorelin acetate, in Adult GROWTH HORMONES Insufficiency . The acceptance for submitting of the NDA shows the FDA has determined that the application is sufficiently complete allowing a substantive review. The application will be subject to a standard review and will have a Prescription Drug User Fee Work day of November 5, 2014. The PDUFA date is the goal time for the FDA to full its review of the NDA. David Dodd, President and CEO of Aeterna Zentaris, commented, The FDA's acceptance of this NDA submission is another significant milestone inside our technique to commercialize macimorelin acetate as the first approved oral product for AGHD evaluation.Research has highlighted the importance of the curcumin used in the diet. It has been well documented that the rates of tumor in India are very lower than those observed in the countries in the West. More than 680 studies have been conducted which shows the remarkable anti-inflammatory, anti-oxidant and anti-carcinogenic properties of the same. This is used as a discomfort reliever and as an anti-inflammatory agent to alleviate inflammation and pain in the muscles and skin. It can also be used as a treatment for menstrual difficulties, jaundice, hemorrhage, hematuria, flatulence, etc. Benfotiamine Benfotiamine or Benphothiamine provides been marketed while lipid soluable form of the thiamine.